Laronde
Pioneering a completely novel translatable RNA platform - Endless RNA (eRNA)
Pioneering a completely novel translatable RNA platform - Endless RNA (eRNA)
Laronde is a biotechnology startup founded in 2017 and based in the United States. The company's slogan "Pioneering a completely novel translatable RNA platform - Endless RNA (eRNA)" reflects its mission to offer a completely novel way of modulating human biology through its pioneering platform.
The core of Laronde's innovation is its Endless RNA™ (eRNA), which is uniquely engineered RNA that can be programmed to express diverse proteins inside the body. This technology is persistent, non-immunogenic, enables repeat dosing, and provides flexibility in formulation and delivery.
Having been founded by Flagship Labs, the innovation foundry of Flagship Pioneering, Laronde is rapidly scaling to support the parallel development of multiple programs across many disease areas.
The company recently secured a significant $440.00M Series B investment on 30 August 2021, with participation from CPP Investments, BlackRock, Flagship Pioneering, Invus, T. Rowe Price, Fidelity, Longevity Vision Fund, and Federated Kaufmann Fund.
| Funding Stage | Amount | No. Investors | Investors | Date |
|---|---|---|---|---|
| Series B | $440.00M | 8 |
|
30 Aug 2021 |
| Series A | $50.00M | 1 |
|
10 May 2021 |
No recent news or press coverage available for Laronde.
We care about your data, and we'd love to use cookies make your experience better.
